Clinical Trials
1
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
Phase 1
Active, not recruiting
- Conditions
- Osteoarthritis, KneeOsteo Arthritis KneeKnee Osteoarthritis
- Interventions
- Genetic: GNSC-001Drug: PlaceboDrug: transient immune-modulation
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Genascence Corporation
- Target Recruit Count
- 67
- Registration Number
- NCT05835895
- Locations
- 🇺🇸
Alliance for Medical Research Mobile, Mobile, Alabama, United States
🇺🇸Biosolutions Clinical Research Center, La Mesa, California, United States
🇺🇸UC San Diego, San Diego, California, United States
News
FDA Grants Fast Track Designation to GNSC-001 Gene Therapy for Knee Osteoarthritis
The FDA has granted Fast Track designation to GNSC-001, a novel gene therapy for knee osteoarthritis, potentially expediting its development and review.